Back to Search
Start Over
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
- Source :
-
Trials . 6/8/2020, Vol. 21 Issue 1, p1-2. 2p. 1 Diagram. - Publication Year :
- 2020
-
Abstract
- An amendment to this paper has been published and can be accessed via the original article. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ERIBULIN
*METASTATIC breast cancer
*TRASTUZUMAB
Subjects
Details
- Language :
- English
- ISSN :
- 17456215
- Volume :
- 21
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Trials
- Publication Type :
- Academic Journal
- Accession number :
- 143659833
- Full Text :
- https://doi.org/10.1186/s13063-020-04408-w